Quadratus Lumborum Block for Total Hip Arthroplasty

NCT05247255 | Recruiting Early Phase 1 FDA Drug

• 1 other identifier: 21-001850
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The quadratus lumborum (QL) block is a fascial plane block that has been described to provide analgesia from T7-L3 dermatomes. The investigators aim to evaluate the efficacy of QL blocks in patients undergoing primary total hip arthroplasty (THA).

Conditions

Pain, Postoperative

Keywords

quadratus lumborum nerve block, analgesia, total hip arthroplasty, postoperative outcomes

Outcome Measures

Primary Outcomes (1)

• Pain score

  Pain scores will be assessed over 48hrs postop using the visual analog score

  Up to 48 hrs post op

Secondary Outcomes (6)

• Opioid usage

  Up to 48 hrs post op

• Time to first stand

  Up to 1 week post surgery

• Time to first ambulation

  Up to 1 week post surgery

• Ambulation distance

  Up to 1 week post surgery

• Length of hospital stay

  Until discharge from hospital, up to 1 week post surgery

Study Arms (2)

Intervention Group

ACTIVE COMPARATOR

Quadratus lumborum nerve block with 0.25% ropivacaine

Drug: Active Comparator

Control Group

PLACEBO COMPARATOR

Quadratus lumborum nerve block with saline

Drug: Placebo Comparator

Interventions

Active Comparator DRUG

QL block with 0.25% ropivacaine

Intervention Group

Placebo Comparator DRUG

QL block with saline

Control Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult subjects undergoing elective primary total hip arthroplasty

You may not qualify if:

• patients age \< 18,
• documented allergy to local anesthetic
• presence of peripheral neuropathy
• patients with current long term opioid use defined as receiving an opioid on most days in a 90 day period
• patients with a contraindication to spinal and regional anesthesia such as coagulopathy or infection at the site of the regional technique.

Sponsors & Collaborators

• University of California, Los Angeles: lead

Study Sites (1)

UCLA Medical Center, Santa Monica

Santa Monica, California, 90404, United States

RECRUITING

MeSH Terms

Conditions

Pain, Postoperative; Agnosia

Condition Hierarchy (Ancestors)

Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Pain; Neurologic Manifestations; Signs and Symptoms; Perceptual Disorders; Neurobehavioral Manifestations; Nervous System Diseases

Study Officials

• Pamela Chia, MD

  University of California, Los Angeles

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jennifer Scovotti, MA

CONTACT

310-206-4484; jscovotti@mednet.ucla.edu

Pamela Chia, MD

CONTACT

310-267-83217; pchia@mednet.ucla.edu

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: HS Assistant Professor

Study Record Dates

• First Submitted: January 30, 2022
• First Posted: February 18, 2022
• Study Start: March 29, 2022
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): January 1, 2027
• Last Updated: December 29, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)